ADCs and their Drug Development Process

“One of the fastest-growing modalities in the pharmaceutical industry, antibody-drug conjugates (ADCs), combines a targeted antibody with a cytotoxic payload to offer numerous therapeutic benefits. Veranova’s experts have a deep understanding of the challenges involved in ADC development and have explored how advanced techniques such as preparative chromatography can help streamline the process.”

In this Q&A in Pharma Focus Europe, Veranova’s Global VP, AR&D Lab Operations, Dr. Kishore Hotha, discusses the current ADC landscape, their therapeutic potential and the challenges faced during development.